Explore All Access
Check if your research matches the topics covered in European Journal of Cancer?
- Degree of match
- Common matching concepts
- Additional journal recommendations
European Journal of Cancer : Impact Factor & More
eISSN: 1879-0852pISSN: 0959-8049
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
European Journal of Cancer Key Metrics
CiteScore 
12.4
H-Index
235
Impact Factor
5 - 10
Scite Index
0.85 5-Year SI
SJR
Q1Oncology
SNIP
2.67
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months69%
4 to 6 months30%
7 to 9 months2%
Above 9 months0%
Did you find this useful?
Topics Covered on European Journal of Cancer
Cancer
Overall survival
Lung cancer
Drug discovery
Lymph node
Progression-free survival
Breast cancer
Immunotherapy
Hysterectomy
Germline
Immune checkpoint
Cohort study
Melanoma
Neuroendocrine tumors
Extracellular vesicles
Toxicity
Machine learning
Chemotherapy
Assay
Lymphoma
European Journal of Cancer Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCI LTD |
| Language | English |
| Frequency | Semi-monthly |
| General Details | |
| Language | English |
| Frequency | Semi-monthly |
| Publication Start Year | 1965 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in European Journal of Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in European Journal of Cancer
SHared decision-making supported by OUTcome information regarding surveillance after curative treatment for Breast Cancer: Results of the SHOUT-BC study
- 1 Dec 2024
- European Journal of Cancer
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01
- 1 Dec 2024
- European Journal of Cancer
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
- 1 Dec 2024
- European Journal of Cancer
PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort
- 1 Dec 2024
- European Journal of Cancer
Epidemiology of men with synchronous metastatic prostate cancer diagnosis – A nationwide 26-year temporal analysis
- 1 Dec 2024
- European Journal of Cancer
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
- 1 Dec 2024
- European Journal of Cancer
SHared decision-making supported by OUTcome information regarding surveillance after curative treatment for Breast Cancer: Results of the SHOUT-BC study
- 1 Dec 2024
- European Journal of Cancer
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01
- 1 Dec 2024
- European Journal of Cancer
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
- 1 Dec 2024
- European Journal of Cancer
PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort
- 1 Dec 2024
- European Journal of Cancer
Epidemiology of men with synchronous metastatic prostate cancer diagnosis – A nationwide 26-year temporal analysis
- 1 Dec 2024
- European Journal of Cancer
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
- 1 Dec 2024
- European Journal of Cancer
Compare Similar Journals with European Journal of Cancer
Select Journals to Compare with European Journal of Cancer
Total journals - 9
You can select up to 3 Journals at a time
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Annals of Oncology
Publisher: ELSEVIER
Cancers
Publisher: MDPI
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
BMC Cancer
Publisher: BMC
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
ESMO Open
Publisher: ELSEVIER
Medicine
Publisher: Elsevier
0 Journals Selected to compare with
European Journal of Cancer
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on European Journal of Cancer
How long has European Journal of Cancer been actively publishing? 
European Journal of Cancer has been in operation since 1965 till date.
What is the publishing frequency of European Journal of Cancer?
European Journal of Cancer published with a Semi-monthly frequency.
How many articles did European Journal of Cancer publish last year?
In 2023, European Journal of Cancer publsihed 501 articles.
What is the eISSN & pISSN for European Journal of Cancer?
For European Journal of Cancer, eISSN is 1879-0852 and pISSN is 0959-8049.
What is Citescore for European Journal of Cancer?
Citescore for European Journal of Cancer is 12.4.
What is the H Index for European Journal of Cancer ?
H Index for European Journal of Cancer is 235.
What is SNIP score for European Journal of Cancer?
SNIP score for European Journal of Cancer is 2.67.
What is the SJR for European Journal of Cancer?
SJR for European Journal of Cancer is Q1.
Who is the publisher of European Journal of Cancer?
ELSEVIER SCI LTD is the publisher of European Journal of Cancer.
Your document is 100% secure & confidential 
